Review

The Current Landscape of Clinical Trials for Systemic Treatment of HCC

Friedrich Foerster and Peter Robert Galle *

First Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, D-55131 Mainz, Germany; foerstfr@uni-mainz.de
* Correspondence: Peter.Galle@unimedizin-mainz.de; Tel.: +49-6131-177275

Simple Summary: Liver cancer is a life-threatening disease. Apart from surgery and catheter-guided therapies, drugs are a central pillar for its treatment. Clinical trials are research studies that are designed to evaluate the treatment effect of a given drug. Therefore, they are the driving force behind innovation and medical progress. One such innovation in the past years has been immunotherapy, which has become increasingly important for treating cancer. Recently, the first such therapy has been approved for the treatment of liver cancer. Current clinical trials are exploring the benefit of immunotherapy and other therapies for this disease. This article gives an overview of such trials paying attention to the different underlying treatment strategies and the varying clinical settings, depending on the stage of the disease.

Abstract: The clinical development of systemic treatments for hepatocellular carcinoma (HCC) has gained significant momentum in recent years. After the unexpected failure of the phase 3 trials testing the PD1-inhibitors nivolumab and pembrolizumab as monotherapy in advanced HCC, a multitude of trials employing different agents in various combinations and at different disease stages have been initiated. The first positive results reported for the combination of atezolizumab and bevacizumab, as the first line treatment of advanced HCC, will bring lasting change to the management of HCC and has increased the odds of success for alternative combination therapies. This review article seeks to provide clarity on the complex and evolving landscape of clinical trials on systemic treatments of HCC. It covers current trials which test various systemic treatments (i) in the first and second line in advanced HCC, (ii) in intermediate HCC, (iii) as adjuvant as well as (iv) neoadjuvant strategies, and (v) including immune interventions other than immune checkpoint inhibition.

Keywords: liver cancer; drugs; therapy; immunotherapy; combination therapy

1. Introduction

Clinical trials (CTs) are the most important tools to produce evidence that a given treatment provides benefits of some measure to patients with a certain condition. For patients with hepatocellular carcinoma (HCC), past CTs have laid the foundations of today’s treatment algorithm [1,2]. CTs have been central to establishing the use of systemic agents for the treatment of advanced HCC, defining how today’s clinicians approach patients at this stage [3]. In this setting, treatment has a palliative intention. Based on the results of past CTs, patients are treated in multiple lines, if possible, starting with the first treatment as first-line and moving to the next treatment as the second-line upon progression or intolerance. The design of future CTs for systemic treatment of HCC can benefit from this experience, particularly with regard to endpoint selection, stratification variables, and target populations [4].

The very first CT to lay the groundwork of treating HCC with a multi-target receptor tyrosine kinase inhibitor (RTKI) in HCC was the SHARP trial, which proved that sorafenib, which blocks VEGFR, PDGFRα, and RAF kinases, significantly extends progression-free
and overall survival in comparison to the placebo (Table 1) [5]. Several subsequent CTs failed to demonstrate a benefit for the tested agent, either as first-line treatment against sorafenib or as second-line treatment against placebo (brivanib [6,7], sunitinib [8], linifanib [9], erlotinib added to sorafenib [10], everolimus [11], tivantinib [12], ADI-PEG 20 [13], doxorubicin added to sorafenib [14], and doxorubicin-loaded nanoparticles [15]). High hopes had been placed on monotherapy with so called immune checkpoint inhibitors because of their impressive results in entities such as melanoma and non-small cell lung cancer, and indeed initial results from the phase 2 trials with the PD1-inhibitors nivolumab and pembrolizumab had been promising and resulted in accelerated approval by the FDA (Table 1) [16,17]. However, the subsequent phase 3 trials with nivolumab as first-line treatment tested against sorafenib and with pembrolizumab as a second-line treatment, compared to the placebo, failed to meet their primary endpoints [18,19].

Despite these setbacks, there have been five successful phase 3 CTs since the SHARP trial (Table 1): The REFLECT trial demonstrated that lenvatinib, which inhibits VEGFRs 1 to 3, FGFRs 1 to 4, RET, KIT, and PDGFRα, is non-inferior to sorafenib in terms of overall survival (OS) [20]. The RESORCE trial showed that regorafenib, which targets VEGF 1 to 3, PDGFR, FGFR, KIT, RET, RAF-1, and BRAF, improves survival in the second-line setting versus the placebo in patients with advanced HCC who had progressed but tolerated a minimum dose of sorafenib (≥400 mg/day for ≥20 of last 28 days of treatment) [21]. Similarly, the CELESTIAL trial established that cabozantinib, which blocks MET, VEGFR 1 to 3, RET, KIT, AXL, and FLT3, improves survival after progression on sorafenib in comparison to placebo [22]. Furthermore, ramucirumab, a monoclonal antibody against VEGFR2 was investigated in the REACH trial [23], where it failed to demonstrate a benefit, but in a subsequent trial concentrating on patients with baseline AFP concentrations ≥400 ng/dL, the REACH-2 trial, it showed improved OS in comparison to placebo in patients who had progressed on sorafenib [24].

The most recent phase 3 CT with a positive result has tested the combination of atezolizumab, an anti-PD-L1 antibody, and bevacizumab, an anti-VEGF antibody, (atezo/bev) as first-line treatment against sorafenib. It demonstrated superior progression-free survival (PFS) and OS for atezo/bev making it the first CT to achieve this since the SHARP trial (Table 1) [25,26]. Atezo/bev has thus become the new standard-of-care as first-line treatment for advanced HCC, and all coming CTs for this indication will need to be measured against this new benchmark.

### Table 1. Past clinical trials on systemic treatments in HCC that resulted in regulatory approval.

| Trial Name | Treatment Arms | Line of Therapy | Primary Endpoint | ORR | PFS | OS |
|------------|----------------|----------------|-----------------|-----|-----|----|
| SHARP [5]  | Sorafenib vs. Placebo | First | OS | 2 vs. 1% | 5.5 vs. 2.8 months | 10.7 vs. 7.9 months (HR 0.69) |
| REFLECT [20] | Lenvatinib vs. Sorafenib | First | OS | 24.1 vs. 9.2% | 7.4 vs. 3.7 months | 13.6 vs. 12.3 months (HR 0.92) |
| IMbrave150 [25,26] | Atezolizumab+bevacizumab vs. sorafenib | First | OS and PFS | 29.8 vs. 11.3% | 6.8 vs. 4.3 months | 19.2 vs. 13.4 months (HR 0.63) |
| RESORCE [21] | Regorafenib vs. Placebo | Second | OS | 11 vs. 4% | 3.1 vs. 1.5 months | 10.6 vs. 7.8 months (HR 0.66) |
| CELESTIAL [22] | Cabozantinib vs. Placebo | Second and third | OS | 4 vs. 1% | 5.2 vs. 1.9 months | 10.2 vs. 8.0 months (HR 0.76) |
| REACH-2 [24] | Ramucirumab vs. Placebo (in patients with AFP > 400 ng/mL) | Second | OS | 5 vs. 1% | 2.8 vs. 1.6 months | 8.5 vs. 7.3 months (HR 0.71) |
| CHECKMATE 040 [16] | Nivolumab * single arm | Second | ORR | 15% | N/A | N/A |
| KEYNOTE 224 [17] | Pembrolizumab * single arm | Second | ORR | 17% | N/A | N/A |
| CHECKMATE 040 [27] | Nivolumab + ipilimumab * single arm | Second | ORR | 32% | N/A | N/A |

* Regulatory approval by the U.S. Food and Drug Administration but not the European Medicines Agency. HR, hazard ratio; N/A, not available; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
2. Systemic Treatment in the First- and Second-Line for Advanced HCC

Several treatments are attempting to follow in atezo/bev’s footsteps (Table 2): The combinations of cabozantinib and atezolizumab (COSMIC-312; NCT03755791) [28], lenvatinib and pembrolizumab, an anti-PD1 antibody (LEAP-002; NCT03713593) [29], durvalumab, an anti-PD-L1 antibody, and tremelimumab, an anti-CTLA-4 antibody (HIMALAYA; NCT03298451) [30], nivolumab and ipilimumab, an anti-CTLA-4 antibody (CheckMate 9DW; NCT04039607), camrelizumab (SHR-1210), an anti-PD-1 antibody, and apatinib (rivo-ceranib), a RTKI that selectively inhibits VEGFR2 (NCT03764293), as well as monotherapy with tislelizumab, an anti-PD-1 antibody (RATIONALE-301; NCT03412773) [31] are currently being tested in phase 3 trials and are similar in design: All take place in the first-line setting and include patients with unresectable HCCs, i.e., the intermediate stage (Barcelona Clinic Liver Cancer [BCLC] B) not amenable to or progressing after loco-regional therapy and the advanced stage (BCLC C). The only exception here is CheckMate 9DW, which is limited to advanced HCC. As for the primary endpoint, the field is mixed: COSMIC-312, LEAP-002 and the camrelizumab plus apatinib trial use PFS per RECIST 1.1 and OS, while HIMALAYA, CheckMate 9DW and RATIONALE-301 use only OS.

| Trial Identifier | Phase | BCLC Stage | Treatment Arms | Primary Endpoint(s) | Setting |
|------------------|-------|------------|----------------|---------------------|---------|
| COSMIC-312       | Phase 3 | B or C | Cabozantinib + atezolizumab | PFS per RECIST 1.1, OS | First-line |
| LEAP-002         | Phase 3 | B or C | Lenvatinib + pembrolizumab | PFS per RECIST 1.1, OS | First-line |
| HIMALAYA         | Phase 3 | B or C | Durvalumab + tremelimumab (2 regimens) | OS | First-line |
| CheckMate 9DW    | Phase 3 | C      | Nivolumab + ipilimumab | OS | First-line |
| N/A              | Phase 3 | B or C | Tislelizumab | PFS, OS | First-line |
| RATIONALE-301    | Phase 3 | B or C | Tislelizumab | OS | First-line |
| GOING            | Phase 1/2 | BCLC C | Regorafenib (monotherapy for the first 8 weeks) + nivolumab | Safety | Second-line |
| RENOBOATE Bayer 19497 | Phase 2 | B or C | Regorafenib + nivolumab | ORR per RECIST 1.1 | First-line |
| N/A              | Phase 2 | B or C | Regorafenib + pembrolizumab Part 1 | Safety, Part 1: Safety | First-line |
| N/A              | Phase 2 | B or C | Regorafenib + pembrolizumab Part 2 | PFS per RECIST 1.1, ORR per RECIST 1.1 | First-line |
| N/A              | Phase 1/2 | B or C | Sitravatinib | Phase 1: Safety, Phase 2: ORR per RECIST 1.1 | First- and later line |
| N/A              | Phase 1/2 | B or C | Sitravatinib + tislelizumab | ORR per RECIST 1.1 | First- and later line |

BCLC, Barcelona Clinic Liver Cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours.

Further combination therapies are in an earlier phase of clinical development (phase 1 or 2). Notably, all include a checkpoint inhibitor: Two trials are evaluating the combination of regorafenib and nivolumab; GOING as second-line treatment after progression on sorafenib with regorafenib as monotherapy during the first eight weeks (NCT04170556), and RENOBOATE as first-line treatment (NCT04310709). Regorafenib is also being studied in combination with pembrolizumab (NCT03347292) and tislelizumab (NCT04183088). The latter consists of two parts, the first evaluating the safety of regorafenib and tislelizumab, the second testing the efficacy of the combination against regorafenib monotherapy. Cabozantinib is also being studied in combination with pembrolizumab as first-line treatment (NCT04442581). Last but not least, a phase 1/2 trial is assessing the safety of sitravatinib, a RTKI which inhibits the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT, as
monotherapy and in combination with tislelizumab, followed by an efficacy evaluation of both the monotherapy and the combination in anti-PD-1/PD-L1 antibody naïve, as well as refractory/resistant HCC (NCT03941873).

Importantly, none of the current phase 3 trials on palliative systemic therapy uses atezo/bev as a comparator, but either sorafenib or lenvatinib.

3. Systemic Treatment for Intermediate HCC

The IMbrave 150 trial enrolled patients with unresectable HCC, i.e., BCLC B and C stage (>80% of patients had BCLC C) [25]. Since the proportion of patients with BCLC B stage was fairly small (~15%), it is currently not possible to make a final assessment of atezo/bev’s efficacy in this patient group, particularly in comparison to treatment with transarterial chemoembolization (TACE), the current standard of care. However, the ABC-HCC trial (NCT04803994), a large investigator initiated phase 3b trial testing atezo/bev against TACE, will precisely address this question (Table 3). Furthermore, the RENOTACE trial (NCT04777851), another large investigator initiated phase 3 trial will test the combination of regorafenib and nivolumab against TACE. Both CTs could pave the way for systemic treatment to the BCLC B stage. However, the challenge of designing such CTs lies in the fact that they compare two different treatment modalities. Therefore, the ABC-HCC trial employs a novel kind of primary endpoint coined time to failure of treatment strategy, which measures the time until either treatment (atezo/bev or TACE) is discontinued by the investigator because it has failed. In contrast, RENOTACE is more conservative in this respect and employs PFS per mRECIST. Other CTs testing different systemic treatments against TACE in intermediate HCC will certainly follow in the coming years.

| Trial       | Identifier    | Phase   | BCLC Stage | Treatment Arms                                      | Primary Endpoint(s)                              | Setting   |
|-------------|---------------|---------|------------|-----------------------------------------------------|--------------------------------------------------|-----------|
| LEAP-012    | NCT04246177   | Phase 3 | B          | • Lenvatinib + pembrolizumab + TACE  
|             |               |         |            | • TACE                                              | • PFS per RECIST 1.1  
|             |               |         |            | • OS                                                | | First-line |
| EMERALD-1   | NCT03778957   | Phase 3 | B          | • Durvalumab + TACE  
|             |               |         |            | • Durvalumab + bevacizumab + TACE  
|             |               |         |            | • TACE                                              | • PFS per RECIST 1.1 | First-line |
| CheckMate 74W | NCT04340193   | Phase 3 | B          | • Nivolumab + ipilimumab + TACE  
|             |               |         |            | • Nivolumab + TACE  
|             |               |         |            | • Time to TACE progression OS                        | | First-line |
| ABC-HCC     | NCT04803994   | Phase 3 | B          | • Atezolizumab + bevacizumab + TACE  
|             |               |         |            | • Time to failure of treatment strategy              | | First-line |
| RENOTACE    | NCT04777851   | Phase 3 | B          | • Regorafenib + nivolumab + TACE  
|             |               |         |            | • PFS per mRECIST                                    | | First-line |

BCLC, Barcelona Clinic Liver Cancer; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours; TACE, transarterial chemoembolization.
Another possibility to treat intermediate HCC might be adding systemic therapy to TACE. There are currently three phase 3 trials that explore whether such an approach is beneficial (Table 3). The LEAP-012 trial is testing the addition of lenvatinib and pembrolizumab to TACE (NCT04246177) [32], the EMERALD-1 trial the addition of durvalumab with or without bevacizumab to TACE (NCT03778957), and the CheckMate 74W trial the addition of nivolumab with or without ipilimumab to TACE (NCT04340193)—all in comparison to TACE alone.

4. Adjuvant Systemic Treatment

As of now, there is no systemic treatment with a proven benefit in the adjuvant setting after curative hepatic resection or ablation. The STORM trial had failed to demonstrate a benefit of sorafenib in this regard [33]. Four phase 3 trials that are exploring new approaches to improve the outcome after curative surgery or ablation are currently ongoing (Table 4): The CheckMate 9DX trial is testing adjuvant treatment with nivolumab (NCT03383458) [34], the KEYNOTE-937 trial adjuvant treatment with pembrolizumab (NCT03867084) [35], the IMbrave050 trial adjuvant treatment with atezolizumab and bevacizumab (NCT04102098) [36], and the EMERALD-2 trial adjuvant treatment with durvalumab with or without bevacizumab (NCT03847428) [37]. Among this group of CTs, the IMbrave050 stands out, as its control arm does not include placebo, but only active surveillance.

Table 4. Current clinical trials on adjuvant systemic treatments after surgery or ablation.

| Trial         | Identifier     | Phase | BCLC Stage | Treatment Arms                  | Primary Endpoint(s) | Setting |
|---------------|----------------|-------|------------|---------------------------------|---------------------|---------|
| CheckMate 9DX | NCT03383458    | Phase 3 | 0 or A    | • Nivolumab  
• Placebo                   | RFS     | Adjuvant |
| KEYNOTE-937   | NCT03867084    | Phase 3 | 0 or A    | • Pembrolizumab  
• Placebo                   | RFS     | Adjuvant |
| IMbrave050    | NCT04102098    | Phase 3 | 0 or A    | • Atezolizumab +  
• bevacizumab  
• Active surveillance      | RFS     | Adjuvant |
| EMERALD-2     | NCT03847428    | Phase 3 | 0 or A    | • Durvalumab +  
• bevacizumab  
• Durvalumab  
• Placebo                   | RFS     | Adjuvant |

BCLC, Barcelona Clinic Liver Cancer; OS, overall survival; RFS, recurrence-free survival.

5. Neoadjuvant Systemic Treatment

In the past, systemic treatment did not play a relevant role in the neoadjuvant setting. Therefore, there are currently no mature data supporting the use of systemic agents before surgery or locoregional treatment. However, the first early phase CTs assessing neoadjuvant systemic treatment are currently being conducted (Table 5): The NIVOLEP trial is assessing the efficacy of nivolumab treatment before and after electroporation (NCT03630640); the CaboNivo trial is evaluating the safety of the combination of cabozantinib and nivolumab before hepatic resection in locally advanced/borderline resectable HCC (NCT03299946); the efficacy of pembrolizumab before and after curative ablation or resection is about to be explored (NCT03337841); and the PLENTY202001 trial is testing the efficacy of the combination of lenvatinib and pembrolizumab before liver transplantation in HCC exceeding the Milan criteria (NCT04425226). Several aspects about the latter trial are remarkable: Its control arm stipulates no intervention, while being on the waiting list for a liver transplant. Additionally, it allows for enrolling patients with impaired liver function (up to Child Pugh B7), which is uncommon, since most major CTs limit enrolment.
to patients with normal liver function (Child Pugh A). The use of immune checkpoint inhibitors in the transplant setting is generally controversial, since such treatment may cause allograft rejection with a potentially fatal outcome [38]. In fact, this is the reason why CTs involving checkpoint inhibitors typically exclude patients who have previously received a solid organ transplant. In this respect, the allograft rejection rate in the treatment group will be very informative.

Table 5. Current clinical trials on neoadjuvant systemic treatments.

| Trial Identifier | Phase | BCLC Stage | Treatment Arms | Primary Endpoint(s) | Setting |
|------------------|-------|------------|----------------|---------------------|---------|
| NIVOLEP NCT03630640 | Phase 2 | A or B | Nivolumab + electroporation | Local RFS | Neoadjuvant & adjuvant |
| CaboNivo NCT03299946 | Phase 1b | N/A * | Cabozantinib + nivolumab + surgery | Safety | Neoadjuvant |
| N/A NCT03337841 | Phase 2 | 0 or A | Pembrolizumab + surgery/ablation | One-year RFS rate | Neoadjuvant & adjuvant |
| PLENTY202001 NCT04425226 | Phase 2 | N/A ** | Pembrolizumab + Lenvatinib + liver transplantation | RFS | Neoadjuvant |

* locally advanced/borderline resectable HCC; ** HCC exceeding Milan criteria. BCLC, Barcelona Clinic Liver Cancer; N/A, not available; RFS, recurrence-free survival.

All in all, the neoadjuvant setting is an uncharted territory for systemic treatment and it remains to be seen which of these novel concepts will finally mature into clinical practice.

6. Systemic Treatment beyond Immune Checkpoint Inhibition

The inhibition of the so called immune checkpoints—and of PD1/PD-L1 and CTLA-4 in particular—is currently the mainstay of cancer immunotherapy. However, there are many more targets that can potentially be exploited by different immune interventions. Such interventions hold the promise to be effective in patients that are or have become resistant to classical immune checkpoint inhibition. For example, patients whose tumours are not infiltrated by effector immune cells are likely to benefit from the adoptive transfer of natural killer (NK) or T cells to boost infiltration of their tumors, which is an approach that is also currently being explored in HCC.

Most forms of cancer immunotherapy that go beyond checkpoint inhibition are still at a preclinical or early clinical stage. Examples of such immunotherapies are chimeric antigen receptor (CAR-) T cells, allogeneic NK cells, and oncolytic viruses (Table 6). Currently, there are six registered phase 1 studies with CAR-T cells targeting Glypican 3 (GPC3) (NCT04121273; NCT04506983; NCT03198546; NCT02905188; NCT03884751; NCT03980288). There is one phase 2 study that is comparing treatment with invariant NKT cells and TACE with TACE alone (NCT04011033). Similarly, FT500, an allogeneic NK cell-line, and FATE-NK100, which are donor-derived NK cells, are being tested in phase 1 trials in various cancer entities including HCC (NCT03319459; NCT04106117; NCT03841110). After the oncolytic virus pexastimogene devacirepvec (Pexa-Vec) failed as second-line monotherapy in advanced HCC in the TRAVERSE phase 2b trial [39], it is now being tested in combination with nivolumab in a phase 1/2a trial (NCT03071094). However, the PHOCUS trial (NCT02562755; phase 3) [40], which studied the combination of Pexa-Vec and sorafenib, stopped enrolling patients prematurely due to the apparent lack of benefit in a planned interim futility analysis, highlighting the odds of failure for novel immune interventions during clinical development.
### Table 6. Selection of current clinical trials on gene and cell-based systemic treatments.

| Identifier       | Phase | BCLC Stage | Treatment Arms | Primary Endpoint(s) | Setting |
|------------------|-------|------------|----------------|---------------------|---------|
| NCT02905188     | Phase 1 | C          | CAR-GPC3 T cells | Safety              | Palliative |
| NCT03980288     | Phase 1 | C          | CAR-GPC3 T cells | Safety              | Palliative |
| NCT04011033     | Phase 2 | C          | iNKT cells + TACE | OS, PFS, DCR       | Palliative |
| NCT03319459     | Phase 1 | C          | FATE-NK100      | Safety              | Palliative |
| NCT03841110     | Phase 1 | C          | FT500 (allogeneic NK cells) | Safety | Palliative |
| NCT03071094     | Phase 1/2 | C       | Pexastimogene devacirepvec + nivolumab | Safety, ORR | Palliative |

BCLC, Barcelona Clinic Liver Cancer; DCR, disease control rate; iNKT cells, invariant natural killer T cells; NK cells, natural killer cells; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TACE, transarterial chemoembolization.

### 7. Outlook and Conclusions

Systemic treatment for HCC has gained considerable momentum in recent years, but never has its outlook been as bright and diverse as today: The breadth of CTs evaluating systemic treatments as adjuvant treatment after curative surgery or ablation, as an addition to TACE, and as palliative first or second-line treatment is unprecedented. The coming years will see a host of data from phase 3 CTs (Figure 1), which have a high chance of bringing a profound change to the clinical management of HCC.

![Figure 1. Expected years of availability of results from ongoing phase 3 clinical trials in HCC.](image)
tested in earlier disease stages. Furthermore, sophisticated immune interventions such as CAR-T or CAR-NK cells have now entered clinical development and may expand the armamentarium for HCC in the long term.

Currently, the most prevalent approach is to combine a RTKI or anti-VEGF antibody with a checkpoint inhibitor. While none of the ongoing CTs uses atezo/bev as a comparator, the efficacy of such regimens will have to be compared to atezo/bev in the advanced HCC first-line setting. And this comparison goes beyond efficacy and needs to pay attention to the toxicity profile and quality of life data as well. Atezo/bev was better tolerated and the quality of life longer maintained compared to sorafenib in the IMbrave150 trial, a relevant aspect for patients in the palliative setting. However, given the issues with intertrial comparisons it will be difficult if not impossible to judge which first-line treatment is best. In addition, data on the sequence of treatments will be lacking making this an important clinical issue in the coming years. Taken together, all these developments make it appear very likely that the relevance of cancer immunotherapy for HCC will continue to increase.

In spite of the excitement around immunotherapy for HCC, it is fairly certain that not every patient will derive equal benefit from current and future systemic treatments. The reason for this lies in the heterogeneity of HCC, which is also reflected in its immune contexture. The composition of the immune contexture influences the prognosis of HCC and can therefore be utilized for immunophenotypic classifications. However, it is still unknown whether any of the proposed signatures or classifications are capable of predicting the response to immunotherapy. Though, first proofs-of-concept have been demonstrated: WNT/CTNNB1 mutations have been associated with resistance against checkpoint inhibition. Furthermore, an interferon-γ-related gene signature that predicts the response to pembrolizumab has been reported, but this has not been shown for HCC. Other biomarker candidates such as tumor mutation burden, T cell repertoire clonality change, and gut microbial diversity are being studied (reviewed in [49]). Further research is needed to develop practical and robust biomarkers that predict the response to treatment and that can be used under real-world conditions. This would allow clinicians to select the most effective systemic treatments for patients with HCC reducing potential harm from individually ineffective regimens.

Another weakness of the current landscape of CTs is that virtually all require an idealized type of HCC patient excluding patients with advanced liver disease, comorbidities and special conditions, which constitute the majority of patients in real-world practice. Recently, we have highlighted the neglect of such patients in CTs. The currently prevalent design of CTs fosters a lack of data for these subgroups of patients perpetuating the challenge of choosing the best treatment strategy for them.

In conclusion, the current landscape of CTs for the systemic treatment of HCC looks highly promising. Cancer immunotherapy now has its place in the treatment algorithm of HCC, and it is likely that its reach will continue to grow. A wealth of exciting data from CTs can be expected in the coming years, which will hopefully provide HCC patients with better treatment options and improved prognosis.

Author Contributions: Conceptualization, F.F. and P.R.G.; writing—original draft preparation, F.F. and P.R.G.; writing—review and editing, F.F. and P.R.G. Both authors have read and agreed to the published version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.
Conflicts of Interest: F.F. reports receiving consulting fees from Roche; lectures fees from Lilly and Pfizer. P.R.G. reports receiving consulting and lectures fees from Adaptimmune, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Lilly, MSD, Roche, Sirtex.

References

1. European Association For The Study of The Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [CrossRef] [PubMed]

2. Heimbach, J.K.; Kulik, L.M.; Finn, R.S.; Sirlin, C.B.; Abecassis, M.M.; Roberts, L.R.; Zhu, A.X.; Murad, M.H.; Marrero, J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018, 67, 358–380. [CrossRef]

3. Finn, R.S.; Zhu, A.X. Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology 2020. [CrossRef] [PubMed]

4. Llovet, J.M.; Villanueva, A.; Marrero, J.A.; Schwartz, M.; Meyer, T.; Galle, P.R.; Lencioni, R.; Gerten, T.F.; Kudo, M.; Mandrekar, S.J.; et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2020. [CrossRef] [PubMed]

5. Llovet, J.M.; Ricci, S.; Mazzaferrro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378–390. [CrossRef] [PubMed]

6. Johnson, P.J.; Qin, S.; Park, J.W.; Poon, R.T.; Raoul, J.L.; Philip, P.A.; Hsu, C.H.; Hu, T.H.; Heo, J.; Xu, J.; et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 2013, 31, 3517–3524. [CrossRef] [PubMed]

7. Llovet, J.M.; Decaens, T.; Raoul, J.L.; Boucher, E.; Kudo, M.; Chang, C.; Kang, Y.K.; Assenat, E.; Lim, H.Y.; Boige, V.; et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 2013, 31, 3509–3516. [CrossRef] [PubMed]

8. Cheng, A.L.; Kang, Y.K.; Lin, D.Y.; Park, J.W.; Kudo, M.; Qin, S.; Chung, H.C.; Song, X.; Xu, J.; Poggi, G.; et al. Sunitinib versus sorafenib in advanced hepatocellular carcinoma: Results of a randomized phase III trial. J. Clin. Oncol. 2013, 31, 4067–4075. [CrossRef] [PubMed]

9. Cainap, C.; Qin, S.; Huang, W.T.; Chung, I.J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y.K.; Chen, P.J.; Toh, H.C.; et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J. Clin. Oncol. 2015, 33, 172–179. [CrossRef]

10. Zhu, A.X.; Rosmorduc, O.; Evans, T.R.; Ross, P.J.; Santoro, A.; Carrilho, F.J.; Bruix, J.; Qin, S.; Thuluvath, P.J.; Llovet, J.M.; et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2015, 33, 559–566. [CrossRef]

11. Zhu, A.X.; Kudo, M.; Assenat, E.; Cattan, S.; Kang, Y.K.; Lim, H.Y.; Poon, R.T.; Blanc, J.F.; Vogel, A.; Chen, C.L.; et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014, 312, 57–67. [CrossRef]

12. Rimassa, L.; Assenat, E.; Peck-Radosavljevic, M.; Pracht, M.; Zagonel, V.; Mathurin, P.; Rota Caremoli, E.; Porta, C.; Daniele, B.; Bolondi, L.; et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): A final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018, 19, 682–693. [CrossRef]

13. Abou-Alfa, G.K.; Qin, S.; Ryoo, B.Y.; Lu, S.N.; Yen, C.J.; Fong, Y.H.; Lim, H.Y.; Izzo, F.; Colombo, M.; Sarker, D.; et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Oncol. 2018, 29, 1402–1408. [CrossRef] [PubMed]

14. Abou-Alfa, G.K.; Shi, Q.; Knox, J.J.; Kaubisch, A.; Niedzwiecki, D.; Posey, J.; Tan, B.R., Jr.; Kavan, P.; Goel, R.; Lammers, P.E.; et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019. [CrossRef]

15. Merle, P.; Blanc, J.F.; Philip, J.M.; Pelletier, G.; Bronowicki, J.P.; Toucheuf, Y.; Pageaux, G.; Gerolami, R.; Habersetzer, F.; Nguyen-Khac, E.; et al. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): A phase 3 randomised controlled trial. Lancet Gastroenterol. Hepatol. 2019, 4, 454–465. [CrossRef]

16. El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T.-Y.; Choo, S.-P.; Trojan, J.; Welling, T.H.; et al. Pembrolizumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017, 389, 2492–2502. [CrossRef]

17. Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.; Verslype, C.; Zagonel, V.; Fartoukh, L.; Vogel, A.; et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 2018, 19, 940–952. [CrossRef]

18. Finn, R.S.; Ryoo, B.Y.; Merle, P.; Kudo, M.; Bouattour, M.; Lim, H.Y.; Breder, V.; Edeline, J.; Choo, Y.; Ogasawara, S.; et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. 2020, 38, 193–202. [CrossRef] [PubMed]

19. Yau, T.; Park, J.W.; Finn, R.S.; Cheng, A.L.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K.H.; Harding, J.J.; Merle, P.; et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol. 2019, 30, v874–v875. [CrossRef]
20. Kudo, M.; Finn, R.S.; Qin, S.; Han, K.-H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.-W.; Han, G.; Jassem, J.; et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *Lancet* 2018, 391, 1163–1173. [CrossRef]

21. Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.-H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017, 389, 56–66. [CrossRef]

22. Abou-Alfa, G.K.; Meyer, T.; Cheng, A.-L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.-Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.-W.; et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *N. Engl. J. Med.* 2018, 379, 54–63. [CrossRef] [PubMed]
23. Zhu, A.X.; Park, J.O.; Ryoo, B.Y.; Yen, C.J.; Poon, R.; Pastorelli, D.; Blanc, J.F.; Chung, H.C.; Baron, A.D.; Pfifer, T.E.; et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol.* 2015, 16, 859–870. [CrossRef]

24. Zhu, A.X.; Kang, Y.K.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; Lim, H.Y.; et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019, 20, 282–296. [CrossRef]

25. Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducrœux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N. Engl. J. Med.* 2020, 382, 1894–1905. [CrossRef] [PubMed]

26. Richard, S.F.; Shukui, Q.; Masafumi, I.; Peter, R.G.; Michel, D.; Tae-You, K.; Ho Yeong, L.; Masatoshi, K.; Valeriy Vladimirovich, B.; Philippe, M.; et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). *J. Clin. Oncol.* 2021, 39, 267. [CrossRef]

27. Yau, T.; Kang, Y.K.; Kim, T.Y.; El-Khoueiry, A.B.; Santoro, A.; Sangro, B.; Melero, I.; Kudo, M.; Hou, M.M.; Matilla, A.; et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. *JAMA Oncol.* 2020. [CrossRef]

28. Rimassa, L.; Cheng, A.; Braiteh, F.; Benzaghou, F.; Hazra, S.; Borgman, A.; Sinha, R.; Kayali, Z.; Zhu, A.; Kelley, R. Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. *Ann. Oncol.* 2019, 30, iv65–iv66. [CrossRef]

29. Josep, M.L.; Masatoshi, K.; Ann-Lii, C.; Richard, S.F.; Peter, R.G.; Shuiuchi, K.; Tim, M.; Shukui, Q.; Corina, E.D.; Eruolo, C.; et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. *J. Clin. Oncol.* 2019, 37, TPS4152. [CrossRef]

30. Ghassan, K.A.-A.; Stephen, L.; Junji, F.; Peter, R.G.; Robin, Kate, K.; Shukui, Q.; Jon, A.; Annie, D.; Gordania, V.; Alejandra, N.; et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. *J. Clin. Oncol.* 2018, 36, TPS4144. [CrossRef]

31. Qin, S.; Finn, R.S.; Kudo, M.; Meyer, T.; Vogel, A.; Ducrœux, M.; Macarulla, T.M.; Tomassello, G.; Boissierie, F.; Hou, J.; et al. RATIONALE 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. *Future Oncol.* 2019, 15, 1811–1822. [CrossRef]

32. Llovet, J.M.; El-Khoueiry, A.B.; Santoro, A.; Sangro, B.; Melero, I.; Kudo, M.; Hou, M.M.; Matilla, A.; et al. Ramucirumab with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. *Ann. Oncol.* 2020, 31, S702–S703. [CrossRef]

33. Zhu, A.X.; Park, J.O.; Ryoo, B.Y.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; Lim, H.Y.; et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019, 20, 282–296. [CrossRef]

34. Exposito, M.J.; Akce, M.; Alvarez, J.; Assenat, E.; Barat, L.; Baron, A.; Decaussens, T.; Heurgue-Berlot, A.; Martin, A.; Paik, S.; et al. Abstract No. 526 CheckMate-9DX: Phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC). *J. Vasc. Interv. Radiol.* 2019, 31, 895C–896C. [CrossRef]

35. Ramucirumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *Lancet Oncol.* 2016, 17, 899–907. [CrossRef] [PubMed]

36. Hack, S.P.; Spahn, J.; Chen, M.; Cheng, A.L.; Kaseb, A.; Kudo, M.; Lee, H.C.; Yopp, A.; Chow, P.; Qin, S. IMbrave150: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. *Future Oncol.* 2020, 16, 975–989. [CrossRef] [PubMed]

37. Knox, J.; Cheng, A.; Cleary, S.; Galle, P.; Kokudo, N.; Lencioni, R.; Park, J.; Zhou, J.; Mann, H.; Morgan, S.; et al. A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative resection. *Cancer Res.* 2020, 80, CT284. [CrossRef] [PubMed]

38. Gassmann, D.; Weiler, S.; Mertens, J.C.; Reiner, C.S.; Vrugt, B.; Nageli, M.; Mangana, J.; Mullhaupt, B.; Jenni, F.; Misselwitz, B. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research. *Transpl. Direct* 2018, 4, e376. [CrossRef] [PubMed]

39. Moele, M.; Heo, J.; Lee, H.C.; Tak, W.Y.; Chao, Y.; Paik, S.W.; Yim, H.J.; Byun, K.S.; Baron, A.; Ungerechts, G.; et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter Phase IIIb trial (TRAVERSE). *Oncoimmunology* 2019, 8, 1615817. [CrossRef] [PubMed]

40. Ghassan, K.A.-A.; Peter, R.G.; Yee, C.; Karen, T.B.; Jeong, H.; Mitesh, J.B.; Angelo, L.; Adina, P.; Delphine, A.; Monika, L.; et al. PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vect followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. *J. Clin. Oncol.* 2016, 34, TPS4146. [CrossRef]
41. Peter, R.G.; Richard, S.F.; Shukui, Q.; Masafumi, I.; Andrew, X.Z.; Tae-You, K.; Masatoshi, K.; Valeriy Vladimirovich, B.; Philippe, M.; Ahmed Omar, K., et al. Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). J. Clin. Oncol. 2020, 38, 476. [CrossRef]

42. Foerster, F.; Hess, M.; Gerhold-Ay, A.; Marquardt, J.U.; Becker, D.; Galle, P.R.; Schuppan, D.; Binder, H.; Bockamp, E. The immune contexture of hepatocellular carcinoma predicts clinical outcome. Sci. Rep. 2018, 8, 5351. [CrossRef] [PubMed]

43. Sia, D.; Jiao, Y.; Martinez-Quetglas, I.; Kuchuk, O.; Villacorta-Martin, C.; Castro de Moura, M.; Putra, J.; Campprecios, G.; Bassaganyas, L.; Akers, N., et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017, 153, 812–826. [CrossRef] [PubMed]

44. Kurebayashi, Y.; Ojima, H.; Tsujikawa, H.; Kubota, N.; Maehara, J.; Abe, Y.; Kitago, M.; Shinoda, M.; Kitagawa, Y.; Sakamoto, M. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 2018, 68, 1025–1041. [CrossRef] [PubMed]

45. Zhang, Q.; Lou, Y.; Yang, J.; Wang, J.; Feng, J.; Zhao, Y.; Wang, L.; Huang, X.; Fu, Q.; Ye, M., et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut 2019, 68, 2019–2031. [CrossRef] [PubMed]

46. Harding, J.J.; Nandakumar, S.; Armenia, J.; Khalil, D.N.; Albano, M.; Ly, M.; Shia, J.; Hechtman, J.F.; Kundra, R.; El Dika, I., et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin. Cancer Res. 2019, 25, 2116–2126. [CrossRef]

47. Pinyol, R.; Sia, D.; Llovet, J.M. Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC. Clin. Cancer Res. 2019, 25, 2021–2023. [CrossRef] [PubMed]

48. Ayers, M.; Lunceford, J.; Nebozhyn, M.; Murphy, E.; Loboda, A.; Kaufman, D.R.; Albright, A.; Cheng, J.D.; Kang, S.P.; Shankaran, V., et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 2017, 127, 2930–2940. [CrossRef]

49. Havel, J.J.; Chowell, D.; Chan, T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 2019, 19, 133–150. [CrossRef]

50. Rimassa, L.; Personeni, N.; Czauderna, C.; Foerster, F.; Galle, P. Systemic Treatment of Hcc in Special Populations. J. Hepatol. 2020. [CrossRef]